A revolutionary blood test that detects a unique DNA marker can now accurately measure arsenic exposure in the body and may predict the risk of developing chronic diseases linked to the toxic metal, scientists announced today.

The test, which relies on a specific epigenetic signature in blood cells, provides the first reliable method to track long-term arsenic exposure and understand how it damages health. "This marker is a game-changer for environmental health," said Dr. Maria Chen, lead author of the study from the University of California, Berkeley. "For the first time, we have a direct readout of cumulative arsenic burden that correlates with disease risk."

Public health experts estimate that more than 200 million people worldwide are exposed to arsenic through contaminated drinking water, primarily in regions of South Asia, South America, and parts of the United States. Background: Health Impacts of Arsenic.

Background: Health Impacts of Arsenic

Long-term arsenic exposure is a known cause of several chronic illnesses, including cancers of the skin, bladder, and lungs, as well as cardiovascular disease and diabetes. Despite this, scientists have lacked a reliable biomarker to measure individual exposure levels or predict who will develop these conditions.

"We have known for decades that arsenic is a potent carcinogen, but we could not easily quantify how much a person has absorbed over their lifetime," explained Dr. James Porter, an environmental health expert at the World Health Organization who was not involved in the study. "This blood-based marker fills that critical gap."

What This Means: Early Detection and Prevention

The discovery opens the door to early screening programs in high-risk populations. By identifying individuals with elevated arsenic-related DNA changes, doctors could recommend interventions such as switching to safer water sources or medical monitoring long before symptoms appear. Learn more about the implications.

"This test could save thousands of lives by enabling proactive public health measures," said Dr. Chen. "Mining communities and agricultural regions using arsenic-laced groundwater could be prioritized for testing."

The study, published today in Nature Communications, analyzed blood samples from over 5,000 participants across five countries. The DNA marker—known as arsenic-related DNA methylation—was consistently elevated in individuals with known high exposure and strongly correlated with cancer incidence in follow-up data.

How the Test Works

When arsenic enters the body, it alters the way certain genes are expressed by adding methyl groups to DNA. The new test measures these methylation patterns at specific gene sites, providing a "molecular memory" of exposure. Unlike urine tests that only reflect recent intake, this blood marker captures exposure over years.

"It's like a biological ledger of arsenic accumulation," noted Dr. Lisa Nguyen, a toxicologist at the U.S. Environmental Protection Agency. "This could become a standard tool in exposure assessment."

Next Steps for Global Health

Researchers are now developing a low-cost version of the test for use in rural clinics in developing nations. They also plan to validate the marker in large prospective studies to confirm its predictive power for various diseases.

"The real victory will be when we can tell a farmer in Bangladesh that his drinking water has already left a mark, and he needs to change his source today," said Dr. Chen. "That's the potential we are chasing."

In the meantime, the finding underscores the urgent need for global arsenic mitigation efforts. As climate change and groundwater depletion worsen, arsenic contamination is expected to affect even more communities—making tools like this test increasingly critical.